HOME >> MEDICINE >> NEWS
UCLA studies experimental cancer drug

Men with high-risk prostate cancer who are candidates for surgery are being sought to test a molecularly targeted experimental drug that may interrupt the signal that is driving their cancer and keep the disease from recurring.

The early-phase clinical trial is based on basic research discoveries made in Jonsson Cancer Center laboratories. UCLA researchers have successfully tested the drug in laboratory and animal models. They hope to translate that benefit into patients in the clinic, said Dr. Charles Sawyers, co-principal investigator for the study and the Jonsson Cancer Center scientist whose basic research resulted in the clinical trial.

UCLA laboratory studies have shown that some patients with prostate cancer have lost PTEN, a tumor-suppressor gene. In some patients who have lost PTEN, a gene called mTOR located downstream in the cell-signaling pathway gets turned on and may be driving the cancer. Sawyers, along with co-principal investigator Dr. Robert Reiter, will test a drug called CCI779, which they believe targets mTOR.

"We discovered that tumors missing PTEN seem to be very responsive to CCI779, and it's very clear at a molecular biology level why," Sawyers said. "When you've lost PTEN, mTOR activity gets turned up and tumors become dependent on it for their growth. So a drug that inhibits mTOR should impact the tumor cells but have no effect on the normal cells."

Armed with his laboratory discoveries, Sawyers proposed the prostate cancer study to Wyeth Pharmaceuticals, and the clinical trial was designed. UCLA's Jonsson Cancer Center is the only West Coast site offering this study. Other sites participating include MD Anderson Cancer Center in Texas and Fox Chase Cancer Center in Philadelphia, Sawyers said.

Because CCI779 targets only what is broken in the cancer cell, it is expected to cause very few side effects, Sawyers said.

UCLA researchers are seeking study volunteers with newly diagnosed prostate ca
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
4-Dec-2003


Page: 1 2

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. New studies show mixed results on epilepsy drugs and birth defects
3. Brain imaging studies investigate pain reduction by hypnosis
4. Impact of scientific advances on drug studies and membrane research to be explored
5. Two studies find evidence that sunlight may have beneficial influence on cancer
6. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
7. Animal studies show stem cells might make biological pacemaker
8. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
9. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
10. Gender and sex hormones affect the brains pain response and more, according to new studies
11. Analysis of tamoxifen studies reveals slight increase of stroke risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Sienna Plantation facility. , “We are pleased to announce Dr. ... Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – North ...
(Date:8/16/2017)... ... ... Break Every Chain”: an inspirational story for those shackled by the chains of a broken ... Shivers, a writer and a woman of great faith and wisdom. She is a ... She was born and raised in Vero Beach, Florida and has dedicated her life and ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental ... the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa ... who has shown three consecutive years of growth. For this year’s award, Progressive Dental ...
(Date:8/15/2017)... ... 2017 , ... Dr. Timothy Davis is now administering two ... This information can be used to develop patient-specific treatment plans for periodontal disease ... tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, Inc., a subsidiary ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
Cached News: